Psychiatry/Behavioral · PANCE / PANRE

Attention-Deficit/Hyperactivity Disorder (ADHD)

Persistent inattention and/or hyperactivity-impulsivity present before age 12 with cross-setting impairment.

Also known as: ADHD, attention deficit, ADD, hyperactivity

Overview

A neurodevelopmental disorder characterized by a persistent pattern of inattention and/or hyperactivity-impulsivity interfering with functioning or development, with several symptoms present before age 12 and across >=2 settings.

Epidemiology

Childhood prevalence ~5-7%; adult prevalence ~2.5-4%. Male-to-female ratio ~2:1 in childhood; narrows in adulthood. Highly heritable (~75%).

Try two board-style Attention-Deficit/Hyperactivity Disorder questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1PsychiatryEasy
A 9-year-old boy with attention-deficit/hyperactivity disorder (ADHD) is brought to the clinic for follow-up. He was started on mixed amphetamine salts 3 months ago with good improvement in inattention at school. However, his mother reports continued irritability, angry outbursts, and physical aggression toward his younger sister at home that have not improved on stimulant therapy. Vital signs and physical examination are normal. Which of the following is the most appropriate next pharmacologic agent to add?
  • ABupropion
  • BFluoxetine
  • CLithium
  • DGuanfacine
Reveal answer & full explanation
Correct answer: D — Guanfacine
  • ABupropion
  • BFluoxetine
  • CLithium
  • DGuanfacine

Why guanfacine is correct

  • This child has ADHD with persistent emotional dysregulation, irritability, angry outbursts, and physical aggression despite an adequate stimulant trial.
  • Guanfacine (or clonidine) is an alpha-2 adrenergic agonist that is FDA-approved as adjunctive therapy with stimulants in children 6–17 years old.
  • Alpha-2 agonists reduce hyperactivity, impulsivity, irritability, and aggression by enhancing prefrontal cortex norepinephrine signaling.
  • AAP and AACAP guidelines endorse the stimulant + alpha-2 agonist combination for ADHD with significant impulsivity or oppositional/aggressive features.

Why the others are wrong

  • B) Fluoxetine — an SSRI used for pediatric depression and OCD, not for ADHD-related aggression.
  • A) Bupropion — has some off-label use as ADHD monotherapy and lowers seizure threshold; not the recommended adjunctive agent for aggression.
  • C) Lithium — a mood stabilizer reserved for pediatric bipolar disorder, not ADHD with aggression.
Question 2PsychiatryEasy
A 32-year-old man has long-standing difficulty with sustained attention, frequent careless errors, disorganization, time management problems, and easy distractibility. He reports that these problems have been present for as long as he can remember. Which diagnostic criterion is required for adult attention-deficit/hyperactivity disorder (ADHD)?
  • AContinuous symptoms for at least 12 months
  • BImpairment confirmed by a collateral informant
  • CSeveral symptoms present before age 12
  • DThree or more symptom domains
Reveal answer & full explanation
Correct answer: C — Several symptoms present before age 12
  • AContinuous symptoms for at least 12 months
  • BImpairment confirmed by a collateral informant
  • CSeveral symptoms present before age 12
  • DThree or more symptom domains

Why Several symptoms present before age 12 is correct

  • Attention-deficit/hyperactivity disorder (ADHD) DSM-5 criteria in adults: ≥5 symptoms of inattention and/or hyperactivity-impulsivity (≥6 required in children <17) present for ≥6 months
  • Several symptoms must have been present BEFORE AGE 12
  • Symptoms must be present in two or more settings (home, work, school, social) and cause significant impairment
  • Subtypes: predominantly inattentive, hyperactive-impulsive, or combined
  • True ADHD does not first manifest in adulthood, though it may not be diagnosed until then

Why the others are wrong

  • Continuous symptoms for at least 12 months — the duration requirement is at least 6 months, and the symptoms need not be continuous
  • Impairment confirmed by a collateral informant — collateral history is recommended to corroborate childhood onset but is not itself a required diagnostic criterion
  • Three or more symptom domains — the criterion is ≥5 symptoms (adults) in the inattention and/or hyperactivity-impulsivity domains, not three separate domains

Additional high-yield points

  • Adult ADHD is associated with academic underachievement, occupational difficulty, and increased substance use
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Attention-Deficit/Hyperactivity Disorder (ADHD) outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Family history (first-degree relative ~5x risk)
  • Prenatal exposure: nicotine, alcohol, prematurity, low birth weight
  • Lead exposure, traumatic brain injury
  • Male sex (in childhood diagnostic samples)

Pathophysiology

Frontostriatal and frontoparietal dysfunction with reduced dopaminergic and noradrenergic signaling. Delayed cortical maturation in prefrontal regions. Reduced default-mode suppression during attention tasks.

Clinical presentation

Symptoms

  • Inattention: careless mistakes, difficulty sustaining attention, doesn't listen, fails to follow through, organization difficulties, avoids sustained mental effort, loses things, easily distracted, forgetful
  • Hyperactivity-impulsivity: fidgets, leaves seat, runs/climbs inappropriately, can't engage quietly, 'on the go', talks excessively, blurts answers, can't wait turn, interrupts
  • Adults: internal restlessness, procrastination, difficulty with time management, executive dysfunction

Signs / physical exam

  • Restlessness or distractibility evident in interview
  • Collateral history from parent/teacher/partner is essential — ADHD is a cross-setting diagnosis

Differential diagnosis

  • Anxiety disorder — Concentration deficits secondary to worry; symptoms newer, situational
  • MDD / bipolar depression — Episodic; mood disturbance predominates
  • Substance use disorder — Symptoms in temporal relationship to use; especially stimulants, cannabis
  • Hyperthyroidism — Tremor, weight loss, suppressed TSH
  • Learning disability — Domain-specific academic deficit without pervasive inattention
  • Autism spectrum disorder — Social communication deficits and restricted/repetitive behaviors; often co-occurs with ADHD
  • OSA / poor sleep — Daytime inattention from sleep fragmentation; screen with sleep history

Diagnostic workup

Diagnostic criteria

DSM-5-TR: (A) >=6 inattention and/or >=6 hyperactivity-impulsivity symptoms for >=6 months in children, or >=5 for individuals age 17 and older; (B) Several symptoms present before age 12; (C) Present in >=2 settings; (D) Clear interference with functioning; (E) Not better explained by another disorder. Specify combined, predominantly inattentive, or predominantly hyperactive-impulsive presentation. Validated rating scales: Vanderbilt (children), ASRS (adults), Conners.

Labs

  • TSH, CBC if suggested by history
  • Pre-stimulant: BP, HR; cardiac history including family history of sudden death; ECG only if cardiac concerns
  • Urine drug screen if substance use suspected

Imaging

  • Not routinely indicated

Diagnostic algorithm

ClassExamplesPearls
Stimulant — methylphenidatemethylphenidate IR/ER, dexmethylphenidateFirst-line; titrate weekly; monitor BP/HR/sleep
Stimulant — amphetaminelisdexamfetamine, mixed amphetamine salts, dextroamphetamineFirst-line; lisdexamfetamine prodrug with lower abuse potential
Non-stimulant SNRIatomoxetine, viloxazineUseful with anxiety, tics, SUD history; 4-6 wks to effect
Alpha-2 agonistguanfacine ER, clonidine ERAdjunct or monotherapy; helps sleep onset, tics; watch sedation/BP
ADHD pharmacotherapy classes and selection considerations.

Treatment

First-line

  • Behavioral parent training and classroom interventions — first-line in preschool age (4-5 years) and adjunct at all ages
  • Stimulant — methylphenidate, lisdexamfetamine, mixed amphetamine salts (first-line pharmacotherapy school-age and older); titrate to effect over weeks
  • School accommodations (IEP/504); psychoeducation; sleep regularity; exercise
  • Adults: CBT for ADHD; coaching; organizational supports

Second-line / adjunct

  • Non-stimulant: atomoxetine (selective norepinephrine reuptake inhibitor, NRI), viloxazine; useful in tic disorder, anxiety, SUD history
  • Alpha-2 agonist: extended-release guanfacine, clonidine — adjunct or monotherapy in children, especially with sleep onset issues or tic disorder
  • Bupropion — off-label in adults with comorbid depression
  • Avoid prescribing immediate-release stimulants to patients with active SUD; use long-acting or non-stimulants and consider diversion risk

Complications

  • Academic underachievement, occupational instability
  • Increased risk of motor vehicle crashes, injuries
  • Substance use disorders, especially when untreated
  • Comorbid mood, anxiety, learning, and oppositional defiant disorders
  • Stimulant side effects: appetite suppression, growth slowing, insomnia, modest BP/HR increases, rare cardiac events in those with structural heart disease
  • Misuse and diversion

PANCE pearls

  • Cross-setting and pre-age-12 symptoms are required — recent onset in adulthood should prompt search for other causes (substance use, mood, sleep, cognitive decline).
  • Stimulants are more efficacious than non-stimulants but require monitoring for BP/HR, appetite, sleep, and growth.
  • Reassess every 6-12 months — many children continue to benefit into adulthood; some achieve symptom remission and may taper.
  • Routine pre-treatment ECG is not required in low-risk children per AAP; obtain ECG/cardiology referral with positive cardiac history or exam.

References

  • AAP 2019 — AAP Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents (2019)
  • AACAP / APA — AACAP Practice Parameter for the Assessment and Treatment of ADHD; APA guidance for adult ADHD
  • DSM-5-TR — American Psychiatric Association. DSM-5-TR (2022)
  • MTA Study — The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for ADHD. Arch Gen Psychiatry 1999

Practice Psychiatry/Behavioral questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.